Inflammation interrelates to APP in sIBM: IL-1β induces accumulation of β-amyloid

Brain

Volumn 132, Issue 4, 2009, Pages

  Schmidt, Jens ^a,b,d   Dalakas, Marinos C ^a,c,d  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GAMMA INTERFERON; INTERLEUKIN 1BETA;

HUMAN; IMMUNOCOMPETENT CELL; INCLUSION BODY MYOSITIS; INFLAMMATION; LETTER; MUSCLE CELL; PRIORITY JOURNAL;

EID: 65249121356     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn164     Document Type: Letter

References (15)

1. Askanas V, Engel WK. Inclusion-body myositis: a myodegenerative con-formational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006; 66: S39-48.
2. Askanas V, Engel WK. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 2007; 19: 550-9.
3. Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci USA 1996; 93: 1314-9.
4. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70: 418-24.
5. Dalakas MC. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 1998; 55: 1509-12.
6. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 2006a; 66: S33-8.
7. Dalakas MC. Sporadic inclusion body myositis-diagnosis, patho-genesis and therapeutic strategies. Nat Clin Pract Neurol 2006b; 2: 437-47.
8. Dalakas MC. Interplay between inflammation and degeneration: Using inclusion body myositis to study "neuroinflammation". Ann Neurol 2008; (early view, DOI: 10.1002/ana.21452).
9. Engel AG. Myology. New York: Mc Graw Hill, 2004.
10. Kitazawa M, Green KN, Caccamo A, LaFerla FM. Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol 2006; 168: 1986-97.
11. Lu DC, Shaked GM, Masliah E, Bredesen DE, Koo EH. Amyloid beta protein toxicity mediated by the formation of amyloid-beta protein precursor complexes. Ann Neurol 2003; 54: 781-9.
12. Querfurth HW, Suhara T, Rosen KM, Mcphie DL, Fujio Y, Tejada G, et al. Beta-amyloid peptide expression is sufficient for myotube death: implications for human inclusion body myopathy. Mol Cell Neurosci 2001; 17: 793-810.
13. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008; 131: 1228-40.
14. Sugarman MC, Kitazawa M, Baker M, Caiozzo VJ, Querfurth HW, LaFerla FM. Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging 2006; 27: 423-32.
15. Tawil R, Griggs RC. Inclusion body myositis. Curr Opin Rheumatol 2002; 14: 653-7.